Unknown

Dataset Information

Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody.


ABSTRACT: COVID-19 is caused by the infection of the lungs by SARS-CoV-2. Monoclonal antibodies, such as sotrovimab, showed great efficiency in neutralizing the virus before its internalization by lung epithelial cells. However, parenteral routes are still the preferred route of administration, even for local infections, which requires injection of high doses of antibody to reach efficacious concentrations in the lungs. Lung administration of antibodies would be more relevant requiring lower doses, thus reducing the costs and the side effects. But aerosolization of therapeutic proteins is very challenging, as the different processes available are harsh and trigger protein aggregation and conformational changes. This decreases the efficiency of the treatment, and can increase its immunogenicity. To a

SUBMITTER: Noverraz F 

PROVIDER: S-EPMC9710110 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature